Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C G Alexopoulos

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 1999
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)E Van Cutsem, D Cunningham, W W Ten Bokkel Huinink, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
British Journal of Cancer|May 3, 2007
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working PartyT Berghmans, J J Lafitte, J Lecomte, et al.
The European Respiratory Journal|August 11, 2007
Chemotherapy improves low performance status lung cancer patientsJ P Sculier, J J Lafitte, M Paesmans, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 1999
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)E Van Cutsem, D Cunningham, W W Ten Bokkel Huinink, et al.
Pageof 3